NAFLD is estimated to affect more than one-quarter of the global population while the prevalence of NASH is estimated to be at least 3 - 5%. With obesity and metabolic disorders expected to continue their global trend upward, NAFLD/NASH rates are also projected to climb, bringing with them increasing rates of hepatocellular carcinoma (HCC).
Reliable and translatable models for researching the drivers of NASH and gauging the effectiveness of new pharmaceutical compounds are becoming ever more critical.
Flexible and Customizable Analytical Assays
Track research progress with real-time updates to study tasks and milestones. Collect robust and meaningful data.
Track the progression of the NASH model through serum measurements of liver enzymes and other study relevant markers. These values provide valuable insight into the health and function of the liver. Track standard markers, or select your own panel with targets of interest.
Insulin resistance, hyperglycemia, and diabetic phenotype are important factors in the progression of NASH pathology. Noninvasively monitor glucose levels throughout the study period to add further depth to your data and results.
From custom tissue weights and collections, to hydroxyproline assays and much more, a wide variety of endpoint and biomarker analyses are readily available for tailoring.
Collect and review expertly prepared histological slides. Liver sections are stained with hematoxylin and eosin (H&E) and picrosirius red (PSR) or Masson’s trichrome to highlight fibrotic deposition and cellular size and health.
Receive scored and detailed slide reviews from an expert veterinary pathologist well-versed in murine NASH and fibrosis research. Computerized, machine learning-based fibrosis scoring also available.
Do you have custom assays or specific biomarker analysis needs? No problem! Ichor can transfer existing procedures and onboard novel analysis methods to fit your needs and acquire the most meaningful data for your study.